Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 9049-9056
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9049
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9049
Figure 1 Serum Insulin-like growth factor-binding protein 5 concentrations in Crohn’s disease patients and healthy controls.
Serum insulin-like growth factor-binding protein 5 (IGFBP-5) (ELISA) levels were significantly decreased in patients with Crohn’s disease compared to healthy controls (P < 0.001). P value from Mann-Whitney test.
- Citation: Adali G, Yorulmaz E, Ozkanli S, Ulasoglu C, Bayraktar B, Orhun A, Colak Y, Tuncer I. Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn’s disease. World J Gastroenterol 2013; 19(47): 9049-9056
- URL: https://www.wjgnet.com/1007-9327/full/v19/i47/9049.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i47.9049